ArticlemedRxiv : the preprint server for health sciences2026
Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
19 authors.
Funding
Abstract
Dengue remains a major global health threat, with over 390 million annual infections. The development of safe, effective, and broadly protective vaccines has been hindered by the need for tetravalent coverage and the risk of antibody-dependent enhancement (ADE). Qdenga (TAK-003) is the only dengue vaccine currently widely available globally, yet its immunological profile remains incompletely defined. Here, we characterized humoral and cellular responses, assessing the impact of the vaccine backbone and immune imprinting on vaccine-induced immunity. We conducted a longitudinal immunological study in 110 adults from a dengue-endemic region, stratified by baseline DENV serostatus, sex, and age, including older adults (≥65 years), a population excluded from efficacy trials. Plasma and PBMCs were collected before and up to five months after Qdenga vaccination to assess neutralizing antibody titers, B cell dynamics, and virus-specific T cell responses. Although Qdenga elicited B and T cell activation and memory formation across groups, our findings revealed serostatus-dependent and serotype-skewed humoral immunity. Only 8% of DENV-naïve individuals developed tetravalent responses, while one-third responded to a single serotype, almost exclusively DENV-2, the vaccine backbone. In contrast, DENV-previously exposed individuals mounted broader responses shaped by baseline serotype-specific immunity, yet neutralization against DENV-4 remained uniformly poor. Neutralizing antibody titers plateaued after the first vaccination, with no substantial increase following the second dose. These findings clarify why balanced tetravalent immunity is rarely achieved with Qdenga and demonstrate that both immune imprinting and vaccine backbone skewing limit the breadth and magnitude of the responses. This has important implications for deployment strategies, long-term protection in DENV-naïve populations, and the need for booster strategies focusing on tetravalent coverage, especially for DENV-4.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.